RU2427572C2 - N-(1-(1-бензил-4-фенил-1н-имидазол-2-ил)-2,2-диметилпропил)бензамидные производные и родственные соединения в качестве ингибиторов кинезинового белка веретена (ksp) для лечения рака - Google Patents

N-(1-(1-бензил-4-фенил-1н-имидазол-2-ил)-2,2-диметилпропил)бензамидные производные и родственные соединения в качестве ингибиторов кинезинового белка веретена (ksp) для лечения рака Download PDF

Info

Publication number
RU2427572C2
RU2427572C2 RU2007101612/04A RU2007101612A RU2427572C2 RU 2427572 C2 RU2427572 C2 RU 2427572C2 RU 2007101612/04 A RU2007101612/04 A RU 2007101612/04A RU 2007101612 A RU2007101612 A RU 2007101612A RU 2427572 C2 RU2427572 C2 RU 2427572C2
Authority
RU
Russia
Prior art keywords
imidazol
benzyl
dimethylpropyl
phenyl
amino
Prior art date
Application number
RU2007101612/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2007101612A (ru
Inventor
Вейбо ВАНГ (US)
Вейбо ВАНГ
Пол А. БЕРСЭНТИ (US)
Пол А. БЕРСЭНТИ
Йи КСИ (US)
Йи КСИ
Рустум С. БОЙСЕ (US)
Рустум С. БОЙСЕ
Сабина ПЕККИ (US)
Сабина Пекки
Натан БРЭММАЙЕР (US)
Натан БРЭММАЙЕР
Меган ФИЛЛИПС (US)
Меган ФИЛЛИПС
Крис МЕНДЕНХОЛЛ (US)
Крис Менденхолл
Келли ВЕЙМЭН (US)
Келли ВЕЙМЭН
Лайена Мэри ЛЭГНАЙТОН (US)
Лайена Мэри ЛЭГНАЙТОН
Райан КОНСТЭНТАЙН (US)
Райан КОНСТЭНТАЙН
Хонг ЯНГ (US)
Хонг ЯНГ
Элизабет МЬЮЛИ (US)
Элизабет МЬЮЛИ
Савитри РАМУРТХИ (US)
Савитри РАМУРТХИ
Элайза ДЖЕЙЗЕН (US)
Элайза ДЖЕЙЗЕН
Ану ШАРМА (US)
Ану Шарма
Джаин РАМА (US)
Джаин РАМА
Шарадха САБРАМАНИАН (US)
Шарадха САБРАМАНИАН
Пол РЕНХОУИ (US)
Пол РЕНХОУИ
Кеннет Уолтер БЭР (US)
Кеннет Уолтер БЭР
Дэвид ДЮЛ (US)
Дэвид ДЮЛ
Аннетте ВАЛЬТЕР (US)
Аннетте Вальтер
Тайния ЭБРЕМС (US)
Тайния ЭБРЕМС
Кай ХУХ (US)
Кай ХУХ
Эрик МАРТИН (US)
Эрик Мартин
Марк КНЭПП (US)
Марк КНЭПП
Винсент ЛЕ (US)
Винсент ЛЕ
Original Assignee
Чирон Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34980173&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2427572(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Чирон Корпорейшн filed Critical Чирон Корпорейшн
Publication of RU2007101612A publication Critical patent/RU2007101612A/ru
Application granted granted Critical
Publication of RU2427572C2 publication Critical patent/RU2427572C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/24—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
RU2007101612/04A 2004-06-18 2005-06-20 N-(1-(1-бензил-4-фенил-1н-имидазол-2-ил)-2,2-диметилпропил)бензамидные производные и родственные соединения в качестве ингибиторов кинезинового белка веретена (ksp) для лечения рака RU2427572C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58092704P 2004-06-18 2004-06-18
US60/580,927 2004-06-18

Publications (2)

Publication Number Publication Date
RU2007101612A RU2007101612A (ru) 2008-08-10
RU2427572C2 true RU2427572C2 (ru) 2011-08-27

Family

ID=34980173

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007101612/04A RU2427572C2 (ru) 2004-06-18 2005-06-20 N-(1-(1-бензил-4-фенил-1н-имидазол-2-ил)-2,2-диметилпропил)бензамидные производные и родственные соединения в качестве ингибиторов кинезинового белка веретена (ksp) для лечения рака

Country Status (21)

Country Link
US (3) US7576221B2 (enExample)
EP (1) EP1765789B1 (enExample)
JP (2) JP4836280B2 (enExample)
KR (1) KR101170925B1 (enExample)
CN (1) CN1993331A (enExample)
AU (1) AU2005258135B2 (enExample)
BR (1) BRPI0510929A (enExample)
CA (1) CA2571002A1 (enExample)
EC (1) ECSP077183A (enExample)
ES (1) ES2409345T3 (enExample)
IL (1) IL180147A0 (enExample)
MA (1) MA28739B1 (enExample)
MX (1) MXPA06014909A (enExample)
NO (1) NO20070343L (enExample)
NZ (1) NZ552510A (enExample)
RU (1) RU2427572C2 (enExample)
SG (1) SG153851A1 (enExample)
TN (1) TNSN06419A1 (enExample)
TW (1) TW200612958A (enExample)
WO (1) WO2006002236A1 (enExample)
ZA (1) ZA200700481B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2698697C2 (ru) * 2013-12-23 2019-08-29 Байер Фарма Акциенгезельшафт Конъюгаты связующего (ADC) с ингибиторами KSP
RU2751512C2 (ru) * 2015-06-22 2021-07-14 Байер Фарма Акциенгезельшафт Конъюгаты антитела и лекарственного средства (adc) и конъюгаты антитела и пролекарства (apdc), содержащие ферментативно расщепляемые группы
RU2761390C2 (ru) * 2016-12-21 2021-12-07 Байер Фарма Акциенгезельшафт Конъюгаты связующего и активного вещества (adc), имеющие ферментативно расщепляемые группы

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4836280B2 (ja) * 2004-06-18 2011-12-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 癌を治療するためのキネシンスピンドルタンパク質（ｋｓｐ）阻害剤としてのｎ−（１−（１−ベンジル−４−フェニル−１ｈ−イミダゾール−２−イル）−２，２−ジメチルプロピル）ベンズアミド誘導体および関連化合物
BRPI0514390A (pt) 2004-08-18 2008-06-10 Astrazeneca Ab enanciÈmero de um composto ou um sal farmacêuticamente aceitável ou um éster hidrolisável in vivo do mesmo, uso do mesmo, métodos para o tratamento de cáncer, para produzir um efeito inibidor de eg5 em um animal de sangue quente e para tratar doenças, e, composição farmacêutica
WO2007011647A2 (en) * 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibitors of mitotic kinesin ksp
TW200800951A (en) * 2005-08-09 2008-01-01 Novartis Ag Substituted imidazole compounds as KSP inhibitors
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
DK2010528T3 (en) 2006-04-19 2018-01-15 Novartis Ag 6-O-Substituted Benzoxazole and Benzothiazole Compounds and Methods for Inhibiting CSF-1R Signaling
PL2090570T3 (pl) 2006-09-05 2012-03-30 Kyowa Hakko Kirin Co Ltd Pochodna imidazolu
SG158147A1 (en) 2006-10-09 2010-01-29 Takeda Pharmaceutical Kinase inhibitors
US8129358B2 (en) * 2006-11-13 2012-03-06 Novartis Ag Substituted pyrazole and triazole compounds as KSP inhibitors
JP2010515687A (ja) * 2007-01-05 2010-05-13 ノバルティス アーゲー キネシンスピンドルタンパク質阻害剤（ｅｇ−５）としてのイミダゾール誘導体
US8252832B2 (en) 2007-12-14 2012-08-28 Novartis Ag Kinesin inhibitors as cancer therapeutics
US20110275685A1 (en) 2009-01-26 2011-11-10 Michael Mutz Salt and polymorphs of a kinesin inhibitor compound
US8748626B2 (en) 2010-04-15 2014-06-10 Novartis Ag Oxazole and thiazole compounds as KSP inhibitors
US8546434B2 (en) * 2010-04-15 2013-10-01 Novartis Ag Triazole compounds as KSP inhibitors
DE102010025663A1 (de) 2010-06-30 2012-01-05 Karl-Heinz Glüsenkamp Neue beta-Aminoaldehyd-Derivate, Verfahren zu ihrer Herstellung und ihre chemische Verwendung als reaktive Intermediate
US8809372B2 (en) 2011-09-30 2014-08-19 Asana Biosciences, Llc Pyridine derivatives
US9498540B2 (en) 2013-03-15 2016-11-22 Novartis Ag Cell proliferation inhibitors and conjugates thereof
WO2014151030A1 (en) * 2013-03-15 2014-09-25 Novartis Ag Cell proliferation inhibitors and conjugates thereof
WO2016020791A1 (en) 2014-08-05 2016-02-11 Novartis Ag Ckit antibody drug conjugates
EP3233127A1 (de) 2014-12-15 2017-10-25 Bayer Pharma Aktiengesellschaft Antikörper-wirkstoff-konjugate (adcs) von ksp-inhibitoren mit aglycosylierten anti-tweakrantikörpern
IS2977B (is) 2015-02-23 2017-07-15 Actavis Group Ptc Ehf. Aðferð til framleiðslu á milliefnum sem eru nytsamleg við nýsmíði á elúxadólíni
JP2018525334A (ja) 2015-06-23 2018-09-06 バイエル ファーマ アクチエンゲゼルシャフト キネシンスピンドルタンパク質（ｋｓｐ）阻害剤の抗ｔｗｅａｋｒ抗体との抗体薬物複合体
US11071788B2 (en) 2015-06-23 2021-07-27 Bayer Pharma Aktiengesellschaft Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with antiB7H3-antibodies
CN107921288A (zh) 2015-06-23 2018-04-17 拜耳医药股份有限公司 Ksp抑制剂的靶向缀合物
WO2017216028A1 (en) 2016-06-15 2017-12-21 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
WO2018114804A1 (de) 2016-12-21 2018-06-28 Bayer Pharma Aktiengesellschaft Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren
KR20210033470A (ko) 2018-06-18 2021-03-26 바이엘 악티엔게젤샤프트 효소에 의해 절단 가능한 링커 및 개선된 활성 프로파일을 갖는, cxcr5에 대해 유도된 결합제-약물 접합체
PE20211475A1 (es) * 2018-12-20 2021-08-05 Amgen Inc Inhibidores de kif18a
WO2023028564A1 (en) 2021-08-26 2023-03-02 Volastra Therapeutics, Inc. Spiro indoline inhibitors of kif18a

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2216541C2 (ru) * 1998-08-04 2003-11-20 Астразенека Аб Производные бензамида, способ их получения и фармацевтическая композиция на их основе
RU2219171C2 (ru) * 1998-09-25 2003-12-20 Астразенека Аб Производные амида, способ их получения и фармацевтическая композиция на их основе

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2550959C3 (de) 1975-11-13 1980-12-04 Hoechst Ag, 6000 Frankfurt Tetrazolyl-imidazole und Tetrazolyl--benzimidazole, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
WO1998027108A2 (en) 1996-12-16 1998-06-25 Fujisawa Pharmaceutical Co., Ltd. New amide compounds and their use as nitric oxide synthase inhibitors
US6117940A (en) 1997-10-17 2000-09-12 Mjalli; Adnan M. M. Amino-ketone solid support templates
JP2002541146A (ja) 1999-04-02 2002-12-03 ニューロゲン コーポレイション アリールおよびヘテロアリール融合のアミノアルキル−イミダゾール誘導体および糖尿病薬としてのその使用
TWI283577B (en) * 1999-10-11 2007-07-11 Sod Conseils Rech Applic Pharmaceutical composition of imidazole derivatives acting as modulators of sodium channels and the use thereof
US7291641B2 (en) * 1999-10-11 2007-11-06 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
US20040132788A1 (en) 1999-10-11 2004-07-08 Chabrier De Lassauniere Pierre-Etienne Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
ES2263501T3 (es) 1999-10-27 2006-12-16 Cytokinetics, Inc. Procedimiento y composiciones que utilizan quinazolinonas.
US6620882B1 (en) 2000-05-02 2003-09-16 Advanced Syntech, Llc Solid support template for preparation of highly functionalized heterocycle compounds
AU2001264872A1 (en) * 2000-06-05 2001-12-17 Ortho-Mcneil Pharmaceutical, Inc. Method for synthesis of substituted azole libraries
US6683191B2 (en) * 2000-06-05 2004-01-27 Ortho-Mcneil Pharmaceuticals, Inc. Method for synthesis of substituted azole libraries
AU7909801A (en) * 2000-08-01 2002-02-13 Sod Conseils Rech Applic Imidazolyl derivatives
CA2425185A1 (en) 2000-10-06 2002-04-11 Stephane De Lombaert Benzimidazole and indole derivatives as crf receptor modulators
JP2002190437A (ja) 2000-12-20 2002-07-05 Advantest Corp 電子ビーム露光装置及び校正方法
US6992082B2 (en) 2001-01-19 2006-01-31 Cytokinetics, Inc. Phenothiazine kinesin inhibitors
US20040132830A1 (en) 2001-01-19 2004-07-08 Finer Jeffrey T Triphenylmethane kinesin inhibitors
US6610723B2 (en) * 2001-01-29 2003-08-26 Hoffmann-La Roche Inc. Imidazole derivatives
US7049303B2 (en) 2001-11-07 2006-05-23 Medical Research Council Inhibition of viruses
AU2002363429B2 (en) 2001-11-07 2008-05-08 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2003043995A1 (en) 2001-11-20 2003-05-30 Cytokinetics, Inc. Process for the racemization of chiral quinazolinones
AU2002363960B2 (en) 2001-12-06 2008-07-10 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
US7378411B2 (en) 2001-12-06 2008-05-27 Merck & Co., Inc. Substituted thienopyrimidinones as a mitotic kinesin inhibitor
WO2003049679A2 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
CA2467726A1 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
ATE424388T1 (de) 2001-12-06 2009-03-15 Merck & Co Inc Mitotische kinesinhemmer
WO2003059289A2 (en) 2002-01-10 2003-07-24 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues
AU2003213092A1 (en) 2002-02-15 2003-09-09 Smithkline Beecham Corporation Syntheses of quinazolinones
AU2003249597B2 (en) 2002-03-08 2007-06-28 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
DE10211770A1 (de) 2002-03-14 2003-10-02 Boehringer Ingelheim Pharma Neue substituierte Piperidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US7026312B2 (en) 2002-03-14 2006-04-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
AU2003245259A1 (en) 2002-05-02 2003-11-17 Neurogen Corporation Substituted imidazole derivatives: gabaa receptor ligands
AU2003301864A1 (en) 2002-05-08 2004-06-07 Neurogen Corporation Substituted imidazolylmethyl pyridine and pyrazine derivatives and their use as gabaa receptor ligands
JP2005530785A (ja) 2002-05-09 2005-10-13 サイトキネティクス・インコーポレーテッド 化合物、組成物、及び方法
EP1503993A4 (en) 2002-05-09 2006-05-03 Cytokinetics Inc COMPOUNDS, METHODS AND COMPOSITIONS
AU2003290507A1 (en) 2002-05-10 2004-04-08 Cytokinetics, Inc. Compounds, compositions and methods
WO2003097643A1 (en) 2002-05-17 2003-11-27 Neurogen Corporation Substituted ring-fused imidazole derivates: gabaa receptor ligands
EP1513820A4 (en) * 2002-05-23 2006-09-13 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
AU2003231799A1 (en) 2002-05-23 2003-12-12 Merck & Co., Inc. Mitotic kinesin inhibitors
KR20050010515A (ko) 2002-06-14 2005-01-27 머크 앤드 캄파니 인코포레이티드 유사분열 키네신 억제제
EP1515949B1 (en) 2002-06-14 2007-03-14 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2004001489A1 (ja) 2002-06-19 2003-12-31 Mitsubishi Denki Kabushiki Kaisha 光変調器
EP1551962A4 (en) 2002-07-08 2007-08-01 Merck & Co Inc MITOTIC KINESIN BINDING CENTER
RU2233736C2 (ru) 2002-07-11 2004-08-10 Раховский Вадим Израилович Нанометрическое позиционирующее устройство
EP1539727B1 (en) 2002-07-17 2009-02-18 Cytokinetics, Inc. Compounds, compositions, and methods for treating cellular proliferative diseases
US7211580B2 (en) 2002-07-23 2007-05-01 Cytokinetics, Incorporated Compounds, compositions, and methods
KR100492252B1 (ko) 2002-08-09 2005-05-30 한국화학연구원 이미다졸을 포함하는 이차아민으로 치환된 벤조피란유도체 및 그의 제조방법
AU2003262747A1 (en) 2002-08-21 2004-03-11 Cytokinetics, Inc. Compounds, compositions, and methods
JP2005539062A (ja) 2002-09-13 2005-12-22 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
KR20050057392A (ko) * 2002-09-18 2005-06-16 화이자 프로덕츠 인크. 전환성장인자(ｔｇｆ) 억제제로서의 신규한 이미다졸 화합물
JP2006501306A (ja) * 2002-09-30 2006-01-12 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
CN100579579C (zh) 2002-10-01 2010-01-13 诺华疫苗和诊断公司 抗癌及抗感染性疾病组合物及其使用方法
PL375889A1 (en) * 2002-10-11 2005-12-12 Cytokinetics, Inc. Compounds for treating cellular proliferative diseases, compositions containing them and their application
DE60307499T2 (de) 2002-11-08 2007-02-01 Neurogen Corp., Branford 4-imidazol-1-ylmethylpyrimidinderivate als liganden für gabaa-rezeptoren
WO2004071448A2 (en) 2003-02-12 2004-08-26 Transtech Pharma Inc. Substituted azole derivatives as inhibitors of protein tyrosine phosphatases
US7662581B1 (en) * 2003-12-18 2010-02-16 Novartis Vaccines And Diagnostics, Inc. Eg5 co-crystals
CA2552558A1 (en) * 2004-01-16 2005-08-11 Wyeth Heterocyclic sulfonamide inhibitors of beta amyloid production containing an azole
US20050187277A1 (en) * 2004-02-12 2005-08-25 Mjalli Adnan M. Substituted azole derivatives, compositions, and methods of use
PT1732926E (pt) * 2004-04-06 2009-04-03 Novartis Vaccines & Diagnostic Inibidores de cinesinas mitóticas
US20080132549A1 (en) 2004-04-14 2008-06-05 Pfizer Inc. Sulphur-Linked Imidazone Compounds for the Treatment of Hiv/Aids
KR20070015598A (ko) 2004-04-28 2007-02-05 다케다 야쿠힌 고교 가부시키가이샤 융합 퀴놀린 유도체 및 이의 용도
US7618981B2 (en) 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
JP4836280B2 (ja) * 2004-06-18 2011-12-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 癌を治療するためのキネシンスピンドルタンパク質（ｋｓｐ）阻害剤としてのｎ−（１−（１−ベンジル−４−フェニル−１ｈ−イミダゾール−２−イル）−２，２−ジメチルプロピル）ベンズアミド誘導体および関連化合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2216541C2 (ru) * 1998-08-04 2003-11-20 Астразенека Аб Производные бензамида, способ их получения и фармацевтическая композиция на их основе
RU2219171C2 (ru) * 1998-09-25 2003-12-20 Астразенека Аб Производные амида, способ их получения и фармацевтическая композиция на их основе

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DENG et al: "Synthetic Applications of Azolium Ylides to a Traceless Solid-Phase Synthesis of 2-Substituted Azoles", ORGANIC LETTERS, vol.4, no.23, 2002, pages 4017-4020. *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2698697C2 (ru) * 2013-12-23 2019-08-29 Байер Фарма Акциенгезельшафт Конъюгаты связующего (ADC) с ингибиторами KSP
RU2751512C2 (ru) * 2015-06-22 2021-07-14 Байер Фарма Акциенгезельшафт Конъюгаты антитела и лекарственного средства (adc) и конъюгаты антитела и пролекарства (apdc), содержащие ферментативно расщепляемые группы
RU2761390C2 (ru) * 2016-12-21 2021-12-07 Байер Фарма Акциенгезельшафт Конъюгаты связующего и активного вещества (adc), имеющие ферментативно расщепляемые группы

Also Published As

Publication number Publication date
CN1993331A (zh) 2007-07-04
TW200612958A (en) 2006-05-01
KR20070106961A (ko) 2007-11-06
US20130017196A1 (en) 2013-01-17
KR101170925B1 (ko) 2012-08-07
MXPA06014909A (es) 2007-02-28
WO2006002236A1 (en) 2006-01-05
US7576221B2 (en) 2009-08-18
JP2011256197A (ja) 2011-12-22
JP4836280B2 (ja) 2011-12-14
EP1765789B1 (en) 2013-02-27
US20060009472A1 (en) 2006-01-12
EP1765789A1 (en) 2007-03-28
US8318791B2 (en) 2012-11-27
ECSP077183A (es) 2007-02-28
BRPI0510929A (pt) 2007-07-17
US8735599B2 (en) 2014-05-27
NZ552510A (en) 2010-12-24
IL180147A0 (en) 2007-06-03
TNSN06419A1 (en) 2008-02-22
NO20070343L (no) 2007-03-05
AU2005258135A1 (en) 2006-01-05
ES2409345T3 (es) 2013-06-26
AU2005258135B2 (en) 2011-09-22
RU2007101612A (ru) 2008-08-10
MA28739B1 (fr) 2007-07-02
ZA200700481B (en) 2008-10-29
SG153851A1 (en) 2009-07-29
CA2571002A1 (en) 2006-01-05
JP2008503501A (ja) 2008-02-07
US20090258016A1 (en) 2009-10-15

Similar Documents

Publication Publication Date Title
RU2007101612A (ru) N-(бензил-4-фенил-1н-имидазол-2-ил)-2, 2-диметилпропил)бензамидные производные и родственные соединения в качестве ингибиторов кинезинового белка веретена (ksp) для лечения рака
JP2008503501A5 (enExample)
CA2575003A1 (en) Potassium channel inhibitors
ES2557478T3 (es) Compuestos de pirazol y triazol como inhibidores de KSP
JP2014521696A5 (enExample)
RU2006127573A (ru) Соединения тетразола и их применение в качестве антагонистов метаботропного рецептора глутамата
RU2009147733A (ru) Пиридилпиперидновые антагонисты рецептора орексинов
RU2007127834A (ru) Производные 1, 6-замещенного (3r, 6r)-3-(2, 3-дигидро-1н-инден-2-ил)-2, 5-пиперазиндиона в качестве антагонистов рецептора окситоцина для лечения преждевременных родов, дисменореи и эндометриоза
USRE49700E1 (en) Substituted nitrogen containing compounds
RU2016133684A (ru) Бициклические азот-содержащие соединения как агонисты М1 мускариновых рецепторов
SK283555B6 (sk) 1-(1,2-Disubstituovaný piperidinyl)-4-substituované deriváty piperidínu, spôsob ich výroby, ich použitie a farmaceutické prostriedky na ich báze
RU2008120619A (ru) (гетеро)арилы, обладающие антагонистической активностью по отношению к меланинконцентрирующему гормону
JP2017500364A5 (enExample)
JP2017502049A5 (enExample)
RU2006145205A (ru) Терапевтические соединения: пиридин в качестве каркаса
RU2007104838A (ru) 2,4,6-тризамещенные пиримидины в качестве ингибиторовфосфотидилинозитол (pi) 3-киназы и их применение для лечения злокачественного новообразования
RU2015144485A (ru) Геминально-замещенные цианоэтилпиразолопиридоны в качестве ингибиторов janus киназ
JP2009504664A5 (enExample)
RU2008108939A (ru) Замещенные имидазолы, фармацевтическая композиция, способ лечения заболевания, связанного по крайней мере с активностью ksp, способ ингибирования ksp, лекарственное средство для лечения рака
RU2007118659A (ru) Производное 1, 5-дигетероцикл-1н-триазола
RU2005100783A (ru) Ингибиторы митотического кинезина
RU2021111663A (ru) Соединение аминопиримидина
RU2020111556A (ru) Производные 3-(1-оксоизоиндолин-2-ил)пиперидин-2,6-диона и варианты их применения
NZ734260B2 (en) Substituted triazoles and methods relating thereto
RU2002127810A (ru) ПРОИЗВОДНЫЕ ЦИКЛИЧЕСКИХ β-АМИНОКИСЛОТ В КАЧЕСТВЕ ИНГИБИТОРОВ МАТРИЧНЫХ МЕТАЛЛОПРОТЕАЗ И TNF-α

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20130621